Citations

Clear

23 citation(s) found for "Dawson, Nancy".

Completion lymph node dissection in patients with sentinel lymph node positive cutaneous head and neck melanoma
Huang, Kai , Misra, Subhasis , Lemini, Riccardo , Chen, Yong , Speicher, Leigh L. , Dawson, Nancy L. , Tolaymat, Leila , Bagaria, Sanjay P. , Gabriel, Emmanuel , Tolaymat, Leila M, Gabriel, Emmanuel M , Bagaria, Sanjay P

Mayo Clinic

Journal of Surgical Oncology | July 12, 2020 | Volume: 122 | Issue: 6 | Pages: 1057-1065

10.1002/jso.26119 | PMID 32654173 Get It

AbstractBackgroundRelatively few cutaneous head and neck melanoma (CHNM) patients with were included in the multicenter selective lymphadenectomy trial II (MSLT‐II). Our objective was to investigate whether immediate completion lymph node dissection completion of lymph node dissection (CLND) was associated with survival benefit for sentinel lymph node (SLN) positive CHNM using the National Cancer Database.MethodsSLN positive patients with CHNM from 2012 to 2014 were retrospectively analyzed. Patients were divided into two groups: those who underwent SLN biopsy (SLNB) only versus those who underwent SLNB followed by CLND (SLNB + CLND). The primary outcome was 5‐year overall survival (OS).ResultsAmong 530 SLNB + patients, 342 patients underwent SLNB followed by CLND (SLNB + CLND). The SLNB only group had fewer positive SLN, less advanced pathologic stage, and a lower rate of adjuvant immunotherapy. There was no significant difference in 5‐year OS between the two groups (51.0% vs 67%; P = .56). After adjusting for pathologic stage, there remained no difference in 5‐year OS among patients with stage IIIA (63.0% vs. 73.6%, P = 0.22) or IIIB/IIIC disease (39.1% vs 57.8%; P = .52).ConclusionsUsing a large nationwide database, CLND was not shown to be associated with improved OS for patients with SLNB positive CHNM, validating the results of MSLT‐II.
Goal-Directed Achievement Through Geographic Location (GAGL) Reduces Patient Length of Stay and Adverse Events
Maniaci, Michael J. , Dawson, Nancy L. , Cowart, Jennifer B. , Richie, Eugene, Suryaprasad, Anil, Hodge, David O. , Joyce, Nicole , Kernan, Carol A., Stone, Laurie A., Burton, M. Caroline , Richie, Eugene M, Suryaprasad, Anil G, Joyce, Nicole E , Dawson, Nancy L , Maniaci, Michael J

Mayo Clinic

American Journal of Medical Quality | October 4, 2019 | Volume: 35 | Issue: 4 | Pages: 323-329

10.1177/1062860619879977 | PMID 31581786 Get It

This prospective cohort study aimed to improve hospital outcomes through geographic location of hospitalist patients and conducting daily multidisciplinary team rounds—Goal-directed Achievements through Geographic Location (GAGL). Patients were admitted to a geographic (GAGL) study unit where daily multidisciplinary rounds took place among nursing, case management, a hospitalist, pharmacy, physical and occupational therapy, respiratory therapy, and nutrition services. A total of 985 (56.4%) patients were admitted to the GAGL study unit and 760 patients (43.6%) were admitted to non-GAGL units. Patients admitted to the GAGL study unit had a shorter average length of stay (3.64 days vs 4.35 days, P = .0001) and a lower number of risk events (91 [9.2%] vs 93 [12.2%], P = .038). There was no significant difference in 30-day readmissions, avoidable day events, or code blue team activations. GAGL provides a framework for hospital organizations to improve provider communication, hospital efficiency, and patient safety.
Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1.
Galsky, Matt D., Dawson, Nancy A. , Srinivas, Sandy, Vaishampayan, Ulka N. , Drakaki, Alexandra , Powles, Thomas, Hoffman‐Censits, Jean , Cui, Na , Mariathasan, Sanjeev , Thastrom, Ann Christine, Abidoye, Oyewale O., Bajorin, Dean F. , Vaishampayan, Ulka , Balar, Arjun Vasant , Loriot, Yohann , Necchi, Andrea , Joseph, Richard W. , Sridhar, Srikala S , Quinn, David I , Drakaki, Alexandra , Durán, Ignacio , Rosenberg, Jonathan E , Powles, Thomas

Mayo Clinic

Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: LBA4500-LBA4500

10.1200/jco.2016.34.15_suppl.lba4500 Get It

TRITON2: An international, multicenter, open-label, phase II study of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD).
Abida, Wassim , Chatta, Gurkamal , Dawson, Nancy A. , Guancial, Elizabeth A. , Hussain, Arif , Jha, Gautam , Lipsitz, David, Petrylak, Daniel P. , Ryan, Charles J. , Stanton, T., Zhang, Jingsong , Simmons, Andrew D. , Go, Jowell, Golsorkhi, Tony, Chowdhury, Simon, Scher, Howard I. , Bryce, Alan H. , Balar, Arjun Vasant , Patnaik, Akash , Vogelzang, Nicholas J.

Mayo Clinic

Journal of Clinical Oncology | February 26, 2018 | Volume: 36 | Issue: 6_suppl | Pages: TPS388-TPS388

10.1200/jco.2018.36.6_suppl.tps388 Get It

TPS388 Background: Up to 25% of patients with advanced prostate cancer, including mCRPC, have a deleterious germline or somatic mutation in BRCA1, BRCA2, ATM or another homologous recombination (HR) DNA repair gene that can serve as a molecular marker to select those who may respond to poly(ADP-ribose) polymerase inhibitors (PARPis). PARPis are lethal to cells with HRD, and PARPi treatment has shown preliminary evidence of an antitumor effect in patients with mCRPC who harbor a mutation in an HR DNA repair gene (Mateo et al. N Engl J Med. 2015;373:1697-708). These data provide a compelling rationale for evaluating rucaparib, a potent PARP1, PARP2 and PARP3 inhibitor, in patients with mCRPC associated with HRD. Methods: TRITON2 (NCT02952534) is a phase 2 study evaluating rucaparib 600 mg BID in patients with mCRPC. Patients with a deleterious germline or somatic BRCA1, BRCA2 or ATM mutation (per prior local test or central test during screening) will be enrolled into 1 of 2 cohorts based on the presence or absence of measurable visceral and/or nodal disease. An exploratory cohort will enroll patients with an alteration in any of 12 other prespecified HR genes (eg, RAD51C, RAD51D and PALB2), with or without measurable visceral and/or nodal disease. Patients must have progressed on androgen receptor signaling–directed therapy and 1 prior taxane-based chemotherapy for mCRPC. Patients who received prior treatment with a PARPi, mitoxantrone, cyclophosphamide or platinum-based chemotherapy are excluded. The primary endpoint is objective response rate measured using modified RECIST v1.1/PCWG3 for patients with soft-tissue disease and prostate-specific antigen response for patients with nonmeasurable disease. Secondary endpoints include duration of response, radiographic progression-free survival, overall survival, clinical benefit rate and safety. Pretreatment blood samples collected from all patients will enable development of a plasma-based companion diagnostic to select patients who may benefit from rucaparib treatment. Patients (≈160) will be enrolled at > 100 sites worldwide. Clinical trial information: NCT02952534.
Patient portal use and hospital outcomes
Burton, M. Caroline , Dawson, Nancy L. , Thomas, Colleen S. , Nordan, Lisa, Greig, Hope E, Aljabri, Duaa , Naessens, James M. , Dumitrascu, Adrian G, Nordan, Lisa M, Aljabri, Duaa I, Dumitrascu, Adrian

Mayo Clinic

Journal of the American Medical Informatics Association | December 1, 2017 | Volume: 25 | Issue: 4 | Pages: 447-453

10.1093/jamia/ocx149 | PMID 29300961 Get It

Abstract Objectives To determine whether use of a patient portal during hospitalization is associated with improvement in hospital outcomes, 30-day readmissions, inpatient mortality, and 30-day mortality. Materials and Methods We performed a retrospective propensity score–matched study that included all adult patients admitted to Mayo Clinic Hospital in Jacksonville, Florida, from August 1, 2012, to July 31, 2014, who had signed up for a patient portal account prior to hospitalization (N = 7538). Results Out of the admitted patients with a portal account, 1566 (20.8%) accessed the portal while in the hospital. Compared to patients who did not access the portal, patients who accessed the portal were younger (58.8 years vs 62.3 years), had fewer elective admissions (54.2% vs 64.1%), were more frequently admitted to medical services (45.8% vs 35.2%), and were more likely to have liver disease (21.9% vs 12.9%) and higher disease severity scores (0.653 vs 0.456). After propensity score matching, there was no statistically significant difference between the 2 cohorts with respect to 30-day readmission (P = .13), inpatient mortality (P = .82), or 30-day mortality (P = .082). Conclusion Use of the patient portal in the inpatient setting may not improve hospital outcomes. Future research should examine the association of portal use with more immediate inpatient health outcomes such as patient experience, patient engagement, medication reconciliation, and prevention of adverse events.
Response to Letter by Dr. Champion
Dawson, Nancy L. , Dawson, Nancy

Mayo Clinic

Pain Medicine | August 14, 2017 | Volume: 19 | Issue: 2 | Pages: 414-414

10.1093/pm/pnx226 | PMID 29161450 Get It

Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1.
Galsky, Matt D., Dawson, Nancy A. , Srinivas, Sandy, Vaishampayan, Ulka N. , Drakaki, Alexandra, Powles, Thomas, Hoffman‐Censits, Jean , Cui, Na , Mariathasan, Sanjeev , Thastrom, Ann Christine, Abidoye, Oyewale O., Bajorin, Dean F. , Balar, Arjun Vasant , Loriot, Yohann , Necchi, Andrea , Joseph, Richard W. , Sridhar, Srikala S , Quinn, David I , Durán, Ignacio , Rosenberg, Jonathan E , Powles, Thomas , Vaishampayan, Ulka

Mayo Clinic

Journal of Clinical Oncology | May 11, 2017 | Volume: 34 | Issue: 18_suppl | Pages: LBA4500-LBA4500

10.1200/jco.2016.34.18_suppl.lba4500 Get It

LBA4500 Background: Cisplatin-based chemo is a standard 1L treatment (tx) for mUC and the only tx that prolongs OS; however, age or comorbidities render many pts ineligible, and 30-50% receive no tx. Atezo (MPDL3280A) is active and well tolerated in platinum-treated mUC, justifying testing atezo as 1L tx in cisplatin-ineligible pts. Methods: Pts were chemo naive in the metastatic setting and cisplatin ineligible (renal [GFR > 30 but < 60 mL/min]/hearing impairment, ≥ G2 peripheral neuropathy [PN] or ≥ ECOG PS2). Atezo 1200 mg was given IV q3w until PD (RECIST v1.1). Centrally assessed PD-L1 on tumor infiltrating immune cells (IC; SP142 IHC assay) was scored IC2/3, 1 or 0. The primary efficacy endpoint was confirmed ORR assessed per RECIST v1.1 (central independent review facility) using a data cutoff of Sep 14, 2015. Results: 119 efficacy/safety-evaluable pts of any PD-L1 IC had a median age of 73 y: 21% ≥ 80 y. 18% had prior systemic tx (21% [neo]adjuvant); 10% had radiotherapy. 66% had visceral mets. 71% had CrCl < 60 mL/min; 13% had hearing loss ≥ 25 dB; 6% had prior PN ≥ G2; 20% had ECOG PS2. ORR was 19% (95% CI 13-28; 5% CR), and responses occurred in all IC subgroups (Table; includes DCR/PFS/OS) and in pts with poor prognostic factors. 22/23 responses were ongoing with mDOR not reached. Median follow-up was 8.5 mo (range 0.2-14.3); median tx duration was 15 wk. Atezo was generally well tolerated. Tx-related all-G and G3-4 AEs were seen in 64% and 12% of pts, respectively. Related all-G AEs ≥ 10% included fatigue, pruritus, diarrhea. 1 G5 related AE occurred (sepsis). 3% had a G3-4 immune-mediated AE. Conclusions: Atezo has clinically meaningful activity in 1L cisplatin-ineligible mUC pts, and preliminary OS is encouraging. The durable nature of response and favorable AE profile makes this an attractive alternative to chemo. NCT02108652. Clinical trial information: NCT02108652. [Table: see text]
Opioid Use in Patients with Congestive Heart Failure
Dawson, Nancy L. , Roth, Victoria, Hodge, David O. , Vargas, Emily , Burton, M. Caroline , Brennan, Emily , Vargas, Emily R

Mayo Clinic

Pain Medicine | April 20, 2017 | Volume: 19 | Issue: 3 | Pages: 485-490

10.1093/pm/pnx103 | PMID 28460060 Get It

Reducing unnecessary testing: an intervention to improve resident ordering practices
Melendez-Rosado, José , Thompson, Kristine M., Cowdell, Jed C. , Sánchez-Álvarez, Catalina , Ung, Ryan, Villanueva, Armando, Jeffers, Kayin , Imam, J. Saadi , Mitkov, Mario V., Kaleem, Tasneem , Jacob, Lewis, Dawson, Nancy L. , Ung, Ryan L, Jeffers, Kayin B, Imam, Jaafer S, Kaleem, Tasneem A, Sanchez-Alvarez, Catalina

Mayo Clinic

Postgraduate Medical Journal | January 20, 2017 | Volume: 93 | Issue: 1102 | Pages: 476-479

10.1136/postgradmedj-2016-134513 | PMID 28104806 Get It

ABSTRACTPurpose of the studyTo reduce the number of unnecessary laboratory tests ordered through a measurement of effects of education and cost awareness on laboratory ordering behaviour by internal medicine residents for common tests, including complete blood cell count (CBC) and renal profile (RP), and to evaluate effects of cost awareness on hospitalisation, 30-day readmission rate and mortality rate.Study design567 patients admitted during February, March and April 2014 were reviewed as the control group. Total CBC, CBC with differential and RP tests were counted, along with readmission and mortality rates. Interventions were education and visual cost reminders. The same tests were reassessed for 629 patients treated during 12 months after intervention in 2015.ResultsData showed a significant increase in CBCs ordered after the intervention (mean number per hospitalisation changed from 1.7 to 2.3 (p&lt;0.001)), a decrease in CBCs with differential (mean number changed from 1.7 to 1.2 (p&lt;0.001)) and no change in RPs ordered (mean number, 3.7 both before and after intervention (p=0.23)). No change was found in mortality rate, but the decrease in the readmission rate was significant (p=0.008).ConclusionsEducation in the form of cost reminders did not significantly reduce the overall ordering of the most common daily laboratory testing in our academic teaching service. We believe further research is needed to fully evaluate the effectiveness of other education forms on the redundant ordering of tests in the hospital setting.
Comparing performance of 30‐day readmission risk classifiers among hospitalized primary care patients
Garrison, Gregory M. , Robelia, Paul M., Pecina, Jennifer L. , Dawson, Nancy L. , Pecina, Jennifer

Mayo Clinic

Journal of Evaluation in Clinical Practice | October 7, 2016 | Volume: 23 | Issue: 3 | Pages: 524-529

10.1111/jep.12656 | PMID 27696638 Get It

AbstractRationale, aims and objectivesHospital readmission within 30 days of discharge occurs in almost 20% of US Medicare patients and may be a marker of poor quality inpatient care, ineffective hospital to home transitions, or disease severity. Within a patient centered medical home, care transition interventions may only be practical from cost and staffing perspectives if targeted at patients with the greatest risk of readmission. Various scoring algorithms attempt to predict patients at risk for 30‐day readmission, but head‐to‐head comparison of performance is lacking. Compare published scoring algorithms which use generally available electronic medical record data on the same set of hospitalized primary care patients.MethodsThe LACE index, the LACE+ index, the HOSPITAL score, and the readmission risk score were computed on a consecutive cohort of 26,278 hospital admissions. Classifier performance was assessed by plotting receiver operating characteristic curves comparing the computed score with the actual outcome of death or readmission within 30 days. Statistical significance of differences in performance was assessed using bootstrapping techniques.ResultsCorrect readmission classification on this cohort was moderate with the following c‐statistics: Readmission risk score 0.666; LACE 0.680; LACE+ 0.662; and HOSPITAL 0.675. There was no statistically significant difference in performance between classifiers.ConclusionsLogistic regression based classifiers yield only moderate performance when utilized to predict 30‐day readmissions. The task is difficult due to the variety of underlying causes for readmission, nonlinearity, and the arbitrary time period of concern. More sophisticated classification techniques may be necessary to increase performance and allow patient centered medical homes to effectively focus efforts to reduce readmissions.